Prognostic Impact of Checkpoint Inhibitor Pneumonitis: Results from a Multicenter Prospective Observational Study (CS-Lung004)

Introduction Checkpoint inhibitor pneumonitis (CIP) is a potentially life-threatening adverse event caused by anti–programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) antibodies. However, paradoxical findings have been reported regarding the association between overall survival (OS) and CIP. This study aimed to prospectively evaluate the relationship between the 2-year OS and CIP in patients receiving first-line treatment, including anti-PD-1/PD-L1 antibody therapy, using 3-month and 1-year landmark analyses. Methods A multicenter prospective observational study was conducted between December 2021 and November 2023 to evaluate the prognostic impact of CIP, based on timing and severity, in patients with non-small cell lung cancer (NSCLC). Results Although no significant difference in OS was observed between patients with and without CIP developed within 2 years or 1 year, the 3-month landmark analysis showed that patients who developed CIP within 3 months had significantly shorter OS than those who did not (median OS from the 3-months landmark: 11.1 months with CIP versus not reached without CIP; log-rank p = 0.011). In multivariate Cox regression analyses, using patients without CIP as the reference group, CIP within 3 months was significantly associated with impaired overall survival (any-grade CIP: hazard ratio [HR] = 2.22, 95% confidence interval [CI]=1.21–4.09; Grade 3–5 CIP: HR=3.37, 95% CI=1.57–7.23). Conclusion This was the first prospective study to demonstrate the prognostic value of CIP. CIP within 3 months after the initiation of first-line treatment, including anti-PD-1/PD-L1 antibody, especially Grade 3–5 CIP, was associated with shorter OS in patients with NSCLC.

Authors

Institutions

Publication Details

Journal
Lung
Published
2026-11-19
DOI
https://doi.org/10.1007/s00408-026-00956-1
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Prognostic Impact of Checkpoint Inhibitor Pneumonitis: Results from a Multicenter Prospective Observational Study (CS-Lung004)

Jun Yano, Naoko Matsumoto, Noboru Hattori, Yuko Toyoda et al.
Lung
Cancer Immunotherapy and Biomarkers
article

Prognostic Impact of Checkpoint Inhibitor Pneumonitis: Results from a Multicenter Prospective Observational Study (CS-Lung004)

Jun Yano, Naoko Matsumoto, Noboru Hattori, Yuko Toyoda, Chihiro Ando, Kakuhiro Yamaguchi, Nobuhiro Kanaji, Koji Kurose, Hiroshi Iwamoto, Yasunari Nagasaki, Suguru Fujita, Masaaki Yanai, Tamio Okimoto, Tetsu Hirakawa, Hisao Higo, Kosuke Oyama, Yoshihiro Taguchi, Kozue Miyazaki, Shimpei Tada, Masako Watanabe
article en

Abstract

Introduction Checkpoint inhibitor pneumonitis (CIP) is a potentially life-threatening adverse event caused by anti–programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) antibodies. However, paradoxical findings have been reported regarding the association between overall survival (OS) and CIP. This study aimed to prospectively evaluate the relationship between the 2-year OS and CIP in patients receiving first-line treatment, including anti-PD-1/PD-L1 antibody therapy, using 3-month and 1-year landmark analyses. Methods A multicenter prospective observational study was conducted between December 2021 and November 2023 to evaluate the prognostic impact of CIP, based on timing and severity, in patients with non-small cell lung cancer (NSCLC). Results Although no significant difference in OS was observed between patients with and without CIP developed within 2 years or 1 year, the 3-month landmark analysis showed that patients who developed CIP within 3 months had significantly shorter OS than those who did not (median OS from the 3-months landmark: 11.1 months with CIP versus not reached without CIP; log-rank p = 0.011). In multivariate Cox regression analyses, using patients without CIP as the reference group, CIP within 3 months was significantly associated with impaired overall survival (any-grade CIP: hazard ratio [HR] = 2.22, 95% confidence interval [CI]=1.21–4.09; Grade 3–5 CIP: HR=3.37, 95% CI=1.57–7.23). Conclusion This was the first prospective study to demonstrate the prognostic value of CIP. CIP within 3 months after the initiation of first-line treatment, including anti-PD-1/PD-L1 antibody, especially Grade 3–5 CIP, was associated with shorter OS in patients with NSCLC.

LungVol. 204(1)
Hiroshima University (JP), Shimane University (JP), Kawasaki Medical School (JP), Kagawa University (JP), Okayama University Hospital (JP), Hiroshima City Asa Citizens Hospital (JP), Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital (JP), Okayama Red Cross General Hospital (JP), Japanese Red Cross Kochi Hospital (JP), Tottori University Hospital (JP), Hiroshima University Hospital (JP), Higashihiroshima Medical Center (JP), National Hospital Organization (JP), Ehime University (JP), Hiroshima City Hiroshima Citizens Hospital (JP), Tottori University (JP), Kōchi University (JP)
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon